NCT05394987 Optical Correction and Visual Functions of Adults With Amblyopia
| NCT ID | NCT05394987 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre for Eye and Vision Research |
| Condition | Amblyopia |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2022-06-13 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2022-06-13 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Amblyopia is a developmental anomaly resulting from abnormal visual experiences in early life. Amblyopia causes reduced visual acuity in the absence of a pathology. Adult sensory systems are believed to be structurally invariant beyond early, critical periods of development. However, recent evidence suggest that visual functions in adults with amblyopia can be improved with optical correction alone. This study aims to investigate whether improvements in best corrected visual acuity and other visual functions can result following appropriate optical correction in adults with amblyopia. Functional measures relating to vision, binocular vision, and eye movements will be used to assess the efficacy of refractive correction for improving vision. This study will help us better understand the improvements in visual functions following optical correction, as well as the mechanisms underlying neuroplasticity in adults with amblyopia.
Eligibility Criteria
Inclusion Criteria: * 18-39 (inclusive) years of age * Anisometropic amblyopia (difference of ≥0.50D spherical equivalent or ≥1.50D astigmatism between eyes) or mixed mechanism amblyopia (strabismus and anisometropia) * Best corrected visual acuity (BCVA) in the amblyopic eye of 0.3 logMAR to 1.0 logMAR (inclusive) * BCVA in the non-amblyopic eye of 0.1 logMAR or better, and an interocular VA difference of 2 logMAR lines or more * Difference of 1.00D or more between current refractive correction and study prescription * Good general health Exclusion Criteria: * Other pathological ocular anomalies known to cause reduced visual acuity * Presbyopia (based on amplitude of accommodation) * Inability to tolerate prescribed refractive correction in spectacles (e.g., due to aniseikonia) * Contraindication to cycloplegic eye drops * Currently under amblyopia treatment/therapy * Inability to comprehend test instructions and/or provide consent * Eccentric fixation * \>-6.00DS of myopia in either eye with spectacles * Bilateral amblyopia * Presence of amblyopia that is not due to strabismus and/or anisometropia * Presence of (current or previous) psychiatric, visual, or neurological disorders
Contact & Investigator
Benjamin Thompson, PhD
PRINCIPAL INVESTIGATOR
Centre for Eye and Vision Research Limited
Frequently Asked Questions
Who can join the NCT05394987 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 39 Years, studying Amblyopia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05394987 currently recruiting?
Yes, NCT05394987 is actively recruiting participants. Contact the research team at ben.thompson@cevr.hk for enrollment information.
Where is the NCT05394987 trial being conducted?
This trial is being conducted at Waterloo, Canada, Hong Kong, Hong Kong.
Who is sponsoring the NCT05394987 clinical trial?
NCT05394987 is sponsored by Centre for Eye and Vision Research. The principal investigator is Benjamin Thompson, PhD at Centre for Eye and Vision Research Limited. The trial plans to enroll 36 participants.